Patent · US Active

Use of C-type natriuretic peptide variants to treat skeletal dysplasia

US12076372B2 · kind B2 · utility

0Cited by

9References

16Claims

0Family size

Assignee

BIOMARIN PHARMACEUTICAL INC. · US

Inventors

Sherry Bullens · Novato, US
Stuart Bunting · Novato, US
Tianwei Chou · Novato, US
Augustus O. Okhamafe · Concord, US
Christopher P. Price · Aachen, DE
Daniel J. Wendt · Novato, US
Clarence Yap · Novato, US

Key dates

Filing date	Jan 20, 2023
Grant date	Sep 3, 2024
Priority date	—
Expiry date	Jan 20, 2043

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P19/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.